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Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies. New antitumor drugs like
aminoﬂavone(AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D
cells and in a MCF-7 nude mouse model. ER(−) breast cancer cells like MDA-MB-231 are less susceptible. We previously found
in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-
speciﬁc DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription
factor. CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA. In contrast an AhR-
deﬁcient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant. Thus, these
drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage. This is a new treatment strategy for
breast cancers with intact AhR signaling.
1.TreatmentAdvancesinBreast Cancer
Metastatic breast cancer is currently incurable, and novel
strategies that might become useful treatments are needed.
In the past decade, Herceptin directed against the HER2/neu
oncoprotein and aromatase antagonists have entered clinical
practice [1, 2]. Despite these advances, cytotoxicity evoked
by drugs directed at DNA remains an interesting option [3].
However, these cytotoxicsare nonspeciﬁc. Ideally, new breast
cancer cytotoxics would engage some aspect of breast cancer
biology to convey selective toxicity to breast cancer cells.
2.Aryl HydrocarbonReceptor
The aryl hydrocarbon receptor (AhR) was initially deﬁned
as a receptor for environmental toxins such as dioxin. It
belongs to the helix-loop-helix transcription factor family.
Other members of this family are AhR nuclear translocator
(ARNT); Drosophila proteins, SIM and PER, and hypoxia-
inducible factor 1α (HIF 1α)[ 4–7]. AhR is a ligand-activated
transcription factor. The most commonly known ligands
of AhR are polycyclic and polyhalogenated hydrocarbons
(benzopyrene, 3-methyl-colantrene), xenobiotics (pheno-
barbital), and other pesticides like tetrachlorodibenzo-p-
dioxin (TCDD).
AhR is localized within the cell cytosol constitutively
w h e r ei ti sp a r to fa ni n a c t i v a t e dc o m p l e xc o m p o s e do ft w o
heat-shock proteins: heat-shock protein 90 (Hsp90) and a
43kDa protein known as AIP (Figure 1) .T h er o l eo fH s p 9 0
involvesachaperone activity thatkeepsAhRin a favorableli-
gand-binding conﬁguration while it prevents its nuclear
translocation. Hydrophobic ligands of AhR enter the cell
by simple diﬀusion and bind to the receptor associated to
Hsp90. Ligand binding to the receptor triggers a conforma-
tional change in AhR to a form that exhibits stronger aﬃnity
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Figure 1: The aryl hydrocarbon signalingpathway.
complexandtoAhRnucleartranslocation.Within thenucle-
us, AhR interacts with ARNT forming a heterodimer that
binds to speciﬁc DNA sequences called xenobiotic response
elements (XREs). This binding leads to the transcriptional
activation of genes that possess these XREs in their promoter
sequences. Some of the genes activated by AhR encode
phase I and II metabolic enzymes such as cytochrome P450
(CYP) 1A1, CYP1A2, and CYP1B1. AhR activation was ﬁrst
described as a cellular response to promote elimination of
ambient contaminants and xenobiotics [8–10]. In humans,
AhR is localized in liver, lungs, kidneys, placenta, lympho-
cytes, ovary, and breast. AhR/ARNT complex activation is
tissue-speciﬁc and depends on co-regulators present in dif-
ferent cell types [9].
3.EstrogenReceptor-ArylHydrocarbon
ReceptorCrosstalk
It was demonstrated that in breast cancer cells, AhR ligands
have the capacity to bind to ER and potentially interfere with
ER signaling [11] .A l s o ,i th a sl o n gb e e nk n o wnt h a te s t r o g e n
can be metabolized by AhR-driven genes such as CYP1B1 to
yieldtoxicmetabolitesthatinsomecaseshavebeenproposed
to act as genotoxins [12]. This has led to the hypothesis
that mutual modulation of AhR and ER signaling functions
may be possible. Indeed, previous publications have shown
that certain AhR ligands can have antiproliferative eﬀects
alone or in conjunction with ER antagonist administration
with evidence of antitumor activity in breast cancer models
[13]. How estrogen and its antagonist will agonize, have no
eﬀect, or amplify AhR-related signaling functions is a key
unresolved question.
4.Benzothiazolesand Aminoﬂavone:
AhR-TargetedTherapiesforBreast Cancer
Empirical screening in the NCI cell line anticancer drug
screen has revealed two types of molecules, the benzothia-
zoles (Bzs) [14–18] and aminoﬂavone (AF) [19], which
are noteworthy for diﬀerential cytotoxicity. “Sensitive” cell
lines have total growth inhibition (TGI) between 0.1 and
1μM, while “resistant” cell lines are refractory to Bz and AF
concentrations<10μM.Amongtheconsistentlysensitive cell
lines to both compound classes were the ER(+) breast cancer
cell lines MCF-7 and T47D [18, 19]. While certain other cell
typesinthisscreendidshowsusceptibility,forexample,renal
cancer, in the breast cancer panel, optimal cytotoxicity of
these drugswas seenincelllinesexpressing estrogenreceptor
(ER(+)) [18]. Detailed mechanistic studies for both Bzs
and AF have revealed that “sensitive” cells can activate AhR
signaling,asmightbeexpectedfromtheirplanarnature[20].
This causes expression of CYP1A1 and in certain cell lines
CYP1B1.Priorworkhadshown thatCYP1A1canmetabolize
Bzs and AF to produce DNA-damaging metabolites [14–19].
5.Benzothiazoles’ Mechanism of Action
Previous results from our research group have demonstrated
that the antitumor eﬀect of compounds of the 2-(4-amino-
3-methylphenyl) benzothiazole group(DF203, NSC674495;
5F 203, NSC 703786) (Figure 2) is mediated by AhR in
MCF-7 breast tumor cells [15, 17, 21]. Currently Phortress,
the lysine amide prodrug of 2-(4-amino-3-methylphenyl)-
5-ﬂuorobenzothiazole (5F 203), is under Phase I clinical
evaluation sponsored by the Cancer Research UK [21–29].
DF203preceded5F203inthedevelopmentofPhortress.
A ﬂuorine atom was introduced to thwart deactivating
metabolism of DF 203 by CYP1A1 to inactive hydroxy-
lated biotransformation products [23]. We observed that
treatment of MCF-7 with Bzs resulted in activation of
AhR. Figure 3 shows AhR translocation to the nucleus after
treatment with DF 203 in sensitive cells like MCF-7 but not
in resistant cells like MDA-MB-435. However, a controversy
exists concerningtheoriginofMDA-MB-435cells.Inthelast
years it has been shown that these cells are derived from a
melanoma [15].International Journal of Breast Cancer 3
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Figure 2: Chemical structures of antitumor 2-(4-amino-3-methylphenyl)benzothiazoles.
D
M
S
O
D
F
2
0
3
-
1
μ
M
β
-
N
F
-
2
0
μ
M
D
M
S
O
D
F
2
0
3
-
1
μ
M
β
-
N
F
-
2
0
μ
M
MCF-7 MDA-MB-435
Cytoplasmic
AhR
Nuclear
AhR
Percent loss of cytoplasmic AhR
Fold increase in nuclear AhR
MCF-7 MDA-MB-435
Cells
MCF-7 MDA-MB-435
Cells
R
e
l
a
t
i
v
e
 
t
o
 
D
M
S
O
R
e
l
a
t
i
v
e
 
t
o
 
D
M
S
O
DF 203
β-NF
8
4
0
100
50
0
Figure 3: DF 203 causes an increase in immunoreactive nuclear AhR in MCF-7 cells. MCF-7 and MDA-MB-435 were treated with 0.1%
DMSO, 1μM DF 203, or 20μM β-naphthoﬂavone for 1h. Determination of immunoreactive AhR in cytoplasmic and nuclear fractions was
performed by western blot. β-NF: β-naphthoﬂavone[15].
In a similar way when we used 5F 203 we observed an
increase in AhR transcriptional activity (increase in XRE-lu-
ciferase activity (Figure 4(a)) and formation of protein/DNA
complexes bound to XRE Figure 4(b))[ 17].
We also observed an increase in the transcription of
AhR target genes such as CYP1A1/1B1, but AHR 100 cells,
derived from MCF-7 which do not express the AhR receptor,
were resistant to 5F 203, and the treatment did not induce
activation of CYP1A1 (Figure 5)[ 17].
We also demonstrated that in MCF-7 cells, treatment
with 5F 203 prevents entry into G2/M and S phase and
causes apoptosis, which was not observed in AHR 100 cells
(Figure 6)[ 17]. These data suggested that activation of AhR
wasnecessaryfortheantitumoractivityofthebenzothiazoles
in MCF-7.
The mechanism of action of benzothiazoles is represent-
ed in Figure 7.
6.Aminoﬂavone,anAlternativeTherapyfor
ER+Breast CancerCell LinesResistantto
AntihormoneTreatment
AF (NSC 686288) is a novel anticancer agent (Figure 8). Pre-
vious work from our research group demonstrated that AF
is a ligand of AhR [19]. It was proposed that induction of
CYP1A1 and high covalent binding of AF metabolites are
markers to predict sensitivity to this drug in breast and renal
tumors [19, 20]. AF derivative compound, aminoﬂavone
prodrug (AFP464, NSC710464), has currently entered phase
II clinical trials (Figure 8).
AFactivityhasbeenlinkedtothepresenceofcytoplasmic
AhR and nuclear translocation of the AhR-AF complex fol-
lowed by induction of cytochrome P450 (CYP) 1A1, activa-
tion of sulfotransferase 1A1 (SULT1A1), and DNA damage
caused by metabolites. The latteris exempliﬁed by the occur-
rence of gamma-histone 2AX (H2AX) phosphorylation con-
sistent with induction of DNA single-strand breaks and
DNA-proteincross-links (Figure 9)[ 30].
AF has shown exquisite in vitro sensitivity toward es-
trogen-receptor-positive (ER+)breast cancercell linesand in
vivoactivity in MCF-7 xenografts (Figure 10)[ 19].
In contrast, ER− breast cancer cell lines, like MDA-MB-
431, were resistant to AF. Crosstalk between AhR and ER
signaling pathways has been established. It was shown that
ligand-bound AhR can mimic estrogens and redirect ER
from ER target genes to AhR target genes, such as CYP1A1
[13]. Given these facts, patients that might beneﬁt most
from AF treatment in the clinic could be those with ER+,
endocrine-therapy-resistant breast cancers.4 International Journal of Breast Cancer
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Figure 4: (a) 5F 203 induces binding to the XRE sequence of CYP1A1. MCF-7 and AHR100 cells were transfected with XRE-luciferase
(pTX.Dir.) or pT81. A schematic of the respective construct is shown below the panel. Transfected cells were treated with DMSO, TCDD
(10nM), or 5F 203 (1μM) for 9h. XRE-luciferase activity was determined normalizing to the amount of Renilla reniformis luciferase. The
values are expressed as luciferase levels relative to control. (b) 5F 203 induces protein/DNA complexes on the XRE sequence of the CYP1A1
promoter. Nuclear extracts (20mg) prepared from MCF-7 cells treated with 0.1% DMSO control (lane 1), TCDD (10nM, 1h) (lane 2), or
5F 203 (1μM, 1h) (lane 3) were incubated with labeled XRE sequence derived from the CYP1A1 promoter for 10min at room temperature.
Free DNA and bound DNA were separated as described. In competition experiments, nuclear extracts from MCF-7 cells treated with 5F
203 (1μM, 1h) were incubated with 4μg of anti-AhR antibody (lane 6), 100-fold excess of unlabeled XRE oligonucleotide (lane7), 100-fold
excess ofunlabeled Sp1oligonucleotide(lane8),or4μg of IgG antiserum(lane9). Protein/DNA complexes from AHR100 cells were resolved
in the same gel. Nuclear extracts from these cells (20mg) treated with DMSO (lane 4) or 5F 203 (1μM, 1h) (lane 5) were incubated with
radioactive XRE and resolved by the same procedure [17].International Journal of Breast Cancer 5
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Figure 5: (a) 5F 203 induces CYP1A1 activity in MCF-7 but not
in AH
R100 cells. MCF-7 and AHR100 cells were incubated for 24h
with DMSO (0.1%) and 5F 203 (1μM )f o r2 4 ha n da s s a y e df o r
CYP1A1 enzyme activity by EROD assay, n = 4 ± s.d. (b) 5F 203
induces CYP1A1 and CYP1B1 mRNA levels in sensitive (MCF-7)
cells. MCF-7 and AHR100 cells were treated with 5F 203 (1μM)
for 24h, RNA was isolated from control and treated samples, and
CYP1A1 and CYP1B1 gene expression were measured by real-time
RT-PCR as described. Data are shown as fold induction of treated
cells relative to constitutive expression in control cells ± s.d., n = 7
(samples from two independent experiments) [17].
Recent work was performed to test whether breast can-
cers resistant to antihormone treatments retain sensitivity to
AF. The AF response in a panel of molecularly well deﬁned
breast cancer cell lines was evaluated. The latter included
MCF-7 (ER+) and its resistant subclones MCF-7/Her2-18
(ER+), MCF-7TAM1 (ER+), LTLC (ER+high), and LTLT
(ERvery low); T47D (ER+), MDA-MB-231 (ER−); Hs5718ti8
(ER−); MCF10A (ER−). Antiproliferative eﬀects were mea-
sured by MTT assay, and concentrations that inhibit cell
growthby50%(IC50)ofthecontrolwereestablishedforeach
cell line. The response to AF was compared to ER and AhR
expression by western blot and immunocytochemistry. AF
potently inhibited the growth of all ER+ breast cancer cell
lines at nanomolar concentrations irrespective of hormone
resistance (mean IC50s: MCF-7 = 16nM; MCF-7/Her2-18 =
20nM; MCF-7TAM1 = 25nM; T47D = 14nM; LTLC =
100nM), whereas the ER− breast cancer cell lines (mean
IC50s: MDA-MB-231 = 25μM; Hs5718ti8 = 18 μM; LTLT
>50μM) and the ER− breast epithelial line MCF10A (IC50 =
3μM) were 2- to 3-log-fold less sensitive. Interestingly, AhR
was predominantly localized in the nuclei of all ER− cell
lines, but was expressed in the cytoplasm of ER+ cells. MCF-
7/Her2-18 and MCF-7TAM1, which are both tamoxifen-re-
sistant subclones of MCF-7 (IC50s4 – O H – t a m o x i f e n3a n d
10μM) and LTLC, a letrozole-resistant clone (IC50 > 1μM),
retained asensitivity to AFthat was similar to parental MCF-
7 cells [31, 32].
In order to examine the role of ER in AF sensitivity, AF
was combined with a ﬁxed concentration (100nM) of the
“pure” antiestrogen Faslodex in MCF-7 cells. The IC50 for
AF plus Faslodex was found tobe 0.5nM, suggesting a syner-
gism between the two drugs. To further prove that ER-AhR
crosstalkiscorrelatedwith AFsensitivity, MDA-MB-231cells
(ER−) were stably transfected with human estrogen recep-
tor-α, rendering themER+. It was found thatthe ER+MDA-
MB-231 cells had cytoplasmic AhR and were 5 times more
sensitive to AF (IC50 = 5μM) compared to parental- and
vector-transfected cells.
The authors concluded that the cytoplasmic AF-AhR
complex can activate unliganded ER to enhance AhR target
gene expression [31, 32].
7.VorinostatCanSensitizeTriple
NegativeBreast CancerCellLinesto
Aminoﬂavone Prodrug
AFP464 exhibits diﬀerential in vitro cytotoxicity in breast
cancer cell lines with inhibitory 50% (IC50) concentrations
ranging from 0.01 to 30μM. AFP464 plasma levels that can
safely be reached in patients are ∼1μM. In sensitive cells,
AFP464 induces AhR-mediated cytochrome P450- (CYP-)
dependent xenobiotic response and cell death. In resistant
cells, the CYP system was not induced. Recent experiments
showed that a panel of 10 luminal and basal A type breast
cancer cells irrespective of resistance to antihormone thera-
pies (e.g., tamoxifen refractory MCF7TAM1 cells) were ex-
quisitely sensitive to AFP464 with IC50s between 0.01 and
0.025μM, whereas “triple-negative” breast cancer (TNBC)
cell lines with a basal B-like gene cluster were resistant
[33,34].Drugconcentrationsneededtoinhibitthegrowthof
basal B-like cells by 50% (25–30μM) may not be achieved in
patients. Thus, it was proposed that in TNBCs, combination
treatments will be needed and that agents modifying gene
transcription, such as the histone deacetylase inhibitor,
vorinostat, might be suitable combination partners. To test6 International Journal of Breast Cancer
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this hypothesis, combination experiments were employed
using the ﬁxed IC50 ratio method and treated MDA-MB-231
and Hs578T cells were treated for 24, 48, and 72hrs with
vorinostat followed by AFP464 for a total of 5 days. It was
found that AFP464 and vorinostat can act synergistically; in
Hs578T cells, combination indices (CIs) of <0.3 were seen
after pretreatment with vorinostat for 24hrs, reducing the
AFP464 IC50 from 20μMt o0 . 5μM; in MDA-MB-231 cells,
CIs indicating synergism (<1) were observed when adding
AFP464 after 48 and 72hrs pretreatment with vorinostat.
This led to a 25-fold sensitization to AFP464 (IC50 = 1μM)
[33, 34].
To study mechanisms that couldexplain the sensitization
of TNBC cell lines to AFP464, real-time PCR to assess the
induction of CYP1A1 and CYP1B1 after vorinostat treat-
ment, western blotting to determine estrogen receptor reac-
tivation,and transcriptional proﬁlingusing Illumina Human
HT-12 v3 whole-genome expression BeadChips were per-
formed. In MDA-MB-231cells vorinostat treatment restored
the AhR-dependent xenobiotic response to AFP464 by in-
d u c i n gb o t hC Y P 1 A 1a n dB 1 ;a l s oe s t r o g e nr e c e p t o re x p r e s -
sion was detectable in MDA-MB-231 and Hs578T cells at
the protein level, consistent with driving these TNBCs into
a more luminal-like genotype. These data indicated the use-
fulness of gene expression proﬁling in selecting patients for
AFP464 treatment. While single agent therapy might present
an option for hormone refractory luminal and basal A type
patient populations, breast cancer patients with basal B-like
tumorswillrequirecombinationtherapies,forexample,with
vorinostat. Pretreatment of TNBCs with vorinostat could
sensitize these tumors to AFP464 [34].
8.NuclearExpressionof the Aryl
HydrocarbonReceptorElicitsResistanceto
Aminoﬂavone Prodrug
Other studies were performed to test whether primary hu-
man tumors would also show nuclear or cytoplasmic AhR
and to assess the extent to which AhR was expressed. 165 ar-
chival human tissues were analyzed comprising breast, pan-
creas, ovarian, and renal cell cancers. It was found that the
59 percent of all cases had detectable AhR, amongst those 78
percent exhibited cytoplasmic AhR and 22 percent nuclear
AhR. Pancreatic (70%) and breast cancers (46%) showed the
highest percentage of cytoplasmic AhR [34].
Together these data indicate that AhR has a distinct dis-
tributionpatternintumorcells.CytoplasmicAhRexpression
elicits sensitivity to the AhR ligand AFP464. If AhR is located
in the nucleus, the xenobiotic response is impaired and
AFP464 cannot be activated [35].
9.Conclusions
These resultslead one to the conclusionthat AF and Bzs, two
structurally dissimilar compounds, share certain character-
isticsintheirmechanism ofactionbutare certainlynot iden-
tical in their pattern of activity. Both compounds activate
the AhR signaling pathway leading to an increase in CYP1A1
and CYP1B1 gene expression in drug-sensitive MCF-7 cells
but not in resistant cells like MDA-MB-435, PC-3, or
MCF-7 AhR-deﬁcient AHR100 cells. Although activation of8 International Journal of Breast Cancer
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Figure 10: Cytotoxicity of aminoﬂavone in vitro and in vivo.
(a) Selective cytotoxicity of aminoﬂavone to MCF-7 breast tumor
cells. Cell lines were seeded into 24-well plates and allowed to
grow for 48 hours. Cells were treated with 10
−10 to 10
−5 mol/L
aminoﬂavone for an additional 72 hours. Cell monolayers were
stained with sulforhodamine (b) and protein was determined
spectrophotometrically. Points, mean ± SD (n = 10). SD was
<5% for all drug concentrations and was omitted for purpose of
graphical clarity. (b) Antitumor activity of aminoﬂavone against
MCF-7 breast tumor xenografts. Treatments were given on a QD ×
5 schedule beginning on day 13. There were 20 mice in the vehicle
control group and 6 mice per dose of aminoﬂavone in the treated
groups [19].
t h eA h Rs i g n a l i n gp a t h w a yb yt h ed r u g sm a yb en e c e s s a r y
for increases in CYP1A1 and CYP1B1 gene expression, addi-
tional metabolic conversions may be necessary to produce
cytotoxicity. These results suggest that the cytotoxicity of AF
and Bz in a sensitive breast tumor cell line is the result of the
engagement of AhR-mediated signal transduction [17, 19].
Thus, these drugs, unlike other neoplastic agents, require
AhR-mediated signaling to cause DNA damage. This oﬀers a
new potential treatment strategy for breast cancers with
intact AhR signaling. Induction of CYP1A1 and AhR acti-
vation were considered as markers to predict sensitivity of
tumors to Bz and AF treatment in Phase I clinical trials.
The data presented in this paper indicate that the cyto-
plasmic AF-AhR complex can activate unliganded ER to en-
hance AhR target gene expression and as a result AF cyto-
toxicity [32]. Therefore, Phase II clinical trials of AF should
include hormone-resistant, metastatic breast cancers.
Also, these data indicated the usefulness of gene expres-
sion proﬁling in selecting patients for AF treatment. While
single-agent therapy might present an option for hormone
refractory luminal and basal A type patient populations,
breast cancer patients with basal B-like tumors will require
combinationtherapies,forexample, withvorinostat[33,34].
Pretreatment of TNBCs with vorinostat could sensitize these
tumors to AF, and this should be exploited in clinical trials.
AhRhasadistinctdistributionpatternintumorcells.Cy-
toplasmicAhRexpression elicitssensitivity totheAhRligand
AF. If AhR is located in the nucleus, xenobiotic response is
impaired and AF cannot be activated [35]. Thus, immuno-
histological analysis of AhR should also be considered as a
tool in the upcoming Phase II trials in breast cancer to select
patients that are most likely to beneﬁt from AF treatment.
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